British Journal of Cancer · 2006 · 69 citations · 25 references
MedicineOncologyUrologyGenitourinary OncologyTumor ImmunologyUrologic OncologyBiomarkers In Genitourinary CancerBiomarkers In Urologic OncologyBladder CancerCancer BiomarkersCancer Survival AnalysisImmune Cell InfiltrationC-reactive Protein TestingCox RegressionDisease-specific SurvivalLymphocytic InfiltratesLymphocytic InflammationUnivariate AnalysisUnivariate Risk Analysis
The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic infiltration, and COX-2 expression and survival was examined in patients with transitional cell carcinoma of the urinary bladder (n=103). Sixty-one patients had superficial disease and 42 patients had invasive disease. Cancer-specific survival was shorter in those patients with invasive compared with superficial bladder cancer (P<0.001). On univariate analysis, stratified by stage, increased Ki-67 labelling index (P<0.05), increased COX-2 expression (P<0.05), C-reactive protein (P<0.05) and adjuvant therapy (P<0.01) were associated with poorer cancer-specific survival. On multivariate analysis of these significant factors, stratified by stage, only C-reactive protein (HR 2.89, 95% CI 1.42-5.91, P=0.004) and adjuvant therapy (HR 0.29, 95% CI 0.14-0.62, P=0.001) were independently associated with poorer cancer-specific survival. These results would suggest that tumour-based factors such as grade, COX-2 expression or T-lymphocytic infiltration are subordinate to systemic factors such as C-reactive protein in determining survival in patients with transitional cell carcinoma of the urinary bladder.
25
Sowmyanarayanan Sadagopan · Ubiquity · 2002 · 1.4K citations
Observer variation in immunohistochemical analysis of protein expression, time for a change?
Thomas Kirkegaard, Joanne Edwards, Sian Tovey et al. · Histopathology · 2006 · 238 citations · Full text
Khalid Canna, Peter McArdle, Donald C. McMillan et al. · British Journal of Cancer · 2005 · 226 citations · Full text
Medicine, Immunology, Oncology +17